Lorcaserin ( DrugBank: Lorcaserin )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
140ドラベ症候群2

140. ドラベ症候群


臨床試験数 : 116 薬物数 : 65 - (DrugBank : 17) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 64
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04572243
(ClinicalTrials.gov)
September 23, 202030/9/2020A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet SyndromeA Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of Lorcaserin as Adjunctive Treatment in Subjects With Dravet SyndromeEpilepsies, MyoclonicDrug: Placebo;Drug: LorcaserinEisai Inc.NULLRecruiting2 YearsN/AAll58Phase 3United States;Canada
2NCT04457687
(ClinicalTrials.gov)
June 7, 201830/6/2020Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory EpilepsiesExtended Access Program and Retrospective Chart Review for Lorcaserin in Dravet Syndrome and Other Refractory EpilepsiesEpilepsies, Myoclonic;Drug Resistant EpilepsyDrug: LorcaserinEisai Inc.NULLAvailable2 YearsN/AAllNULL